JSES - 2026-06-01 - Journal Article
Clinical and Radiographic Survival Rates of the Arthrex Univers VaultLock Uncemented Central-Peg All-Polyethylene Glenoid Component in Anatomic Total Shoulder Arthroplasty at 2- and 5-Years Postoperatively.
Nazzal EM, Lin RT, McMahon S, Shoulder Arthroplasty Research Committee (ShARC), Denard PJ, Farmer K, Huffman GR, Lin A
Topics
Key Takeaway
The Arthrex VaultLock uncemented central-peg all-polyethylene glenoid achieves 99.2% clinical and 95.0% radiographic survival at 5 years, with central peg bone grafting reducing Lazarus score ≥2 rates from 23.2% to 9.5%.
Summary Depth
Choose how much analysis to show on this article page.
Summary
This multicenter retrospective case series evaluated radiographic loosening (Lazarus classification) and clinical outcomes of the VaultLock uncemented central-peg all-polyethylene glenoid in primary aTSA at 2 and 5 years. At 5 years, 84% had Lazarus grade 0–1, 11% grade 2, and 5% grade ≥3 ('at-risk'); 33.6% showed Lazarus score progression between 2 and 5 years. Central peg humeral head bone grafting was independently associated with lower radiolucency rates (9.5% vs. 23.2%, p=0.042), and clinical revision rate was 0.8% at 5 years.
Key Limitation
The absence of a concurrent control group (cemented all-polyethylene or pegged/keeled comparator) prevents conclusions about whether the uncemented design is superior to established fixation methods rather than merely non-inferior.
Original Abstract
BACKGROUND
To evaluate radiographic and functional outcomes at 2 and 5 years postoperatively for anatomic total shoulder arthroplasty (aTSA) performed with an uncemented central-peg all-polyethylene glenoid (Univers VaultLock; Arthrex, Inc., Naples, FL) designed for an uncemented central-peg fixation with peripheral cement and central osseous interdigitation.
METHODS
This was a multi-center retrospective case series of aTSAs identified from a prospectively maintained registry. All primary aTSAs with an intact rotator cuff using a VaultLock glenoid (uncemented central-peg all-polyethylene design) and available radiographic data were included for analysis at 2- and 5-years postoperatively. Primary outcomes included radiographic glenoid loosening (via Lazarus classification) and revision rates for glenoid loosening. Relevant changes in lucency were defined as change in Lazarus score ≥ 2 and an "at-risk" component for loosening was defined as Lazarus score ≥ 3. Secondary outcomes included range of motion, as well as patient-reported outcomes.
RESULTS
A total of 133 patients were included in the overall cohort, of whom 119 met criteria for analysis of radiographic and patient-reported outcomes at 5 years. The mean age was 63.9 ± 7.8 years, with an average body mass index (BMI) of 30.2 ± 4.9 kg/m 2 and mean follow-up of 5.0 ± 0.4 years. All outcome measures significantly improved at 2- and 5-years compared to baseline. At 2 years, 111 patients (93.3%) demonstrated a grade 0-1 Lazarus score, while 8 patients (6.7%) had a grade 2 Lazarus score. No glenoids at 2 years were observed to have grade 3 changes consistent with being "at-risk" for radiographic loosening. At 5 years, 100 patients (84.0%) had a grade 0-1 Lazarus score, 13 patients (11.0%) had a grade 2 Lazarus score, and 6 patients (5.0%) had a grade 3 or greater Lazarus scores. 40 (33.6%) patients had an increase in Lazarus score from 2 to 5 years with mean increase of 1.2 (SD 0.42, Range: 1-2). At 5 years, central peg humeral head bone grafting was associated with lower rates of Lazarus score ≥2 versus no grafting (9.5% vs 23.2%, p = 0.042). Clinical survival rate was 99.2% (132/133) at 5-years postoperatively, with radiographic survival of 95.0% (113/119) at 5-years postoperatively.
CONCLUSIONS
The VaultLock glenoid has a 5-year clinical and radiographic glenoid survival rate of 99.2% and 95.0%, respectively. These findings are consistent with or superior to prior published reports of all-polyethylene glenoids and supports the use of a uncemented central-peg all-polyethylene component in primary TSA.
LEVEL OF EVIDENCE
Level IV, Case Series, Treatment Study.